Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Inflammation × Dexmedetomidine × Clear all

Phase

Status

Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 5 Pituitary Neoplasms 3 Brain Neoplasms 3 Stomach Neoplasms 2 Pain 2 Delirium 2 Supratentorial Neoplasms 1 Spinal Cord Neoplasms 1 Sleep Deprivation 1 Retinoblastoma 1 Pituitary Diseases 1 Non-functioning Pituitary Adenoma 1 Neoplasms 1 Morphine Consumption 1 Lung Neoplasms 1 Intrathecal Dexmedetomidine 1 Intracranial Aneurysm 1 Intestinal Obstruction 1 Intestinal Fistula 1 Inflammation 1 Hyperparathyroidism 1 Fibrosis 1 Female Patients Under the Age of 65 Who Will Undergo Breast Cancer Surgery 1 Cough 1 Colorectal Neoplasms 1 Central Nervous System Diseases 1 Breast Neoplasms 1 Breast Cancer Patients 1 Agnosia 1 Abdominal Neoplasms 1

Interventions

Ibuprofen 2 palbociclib 1 Weights and Measures 1 Rivaroxaban 1 Resistance Training 1 Qigong 1 Nutrition Assessment 1 Massage 1 Ketorolac 1 Hyperspectral Imaging 1 High-Intensity Interval Training 1 Fish Oils 1 Eating 1 Diet Records 1 Dexmedetomidine 1 Chromatin Immunoprecipitation Sequencing 1 CHR 2845 1 Body Height 1 Blood Specimen Collection 1 Basal Metabolism 1 Aspirin 1 Anti-Inflammatory Agents, Non-Steroidal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡